National Cancer Institute, Naples: Carcinoma, Ovarian Epithelial trials
The registry lists 13 Carcinoma, Ovarian Epithelial studies with National Cancer Institute, Naples as lead sponsor. 2 are open to participants now and 0 have results posted.
Phase 2 4Phase 3 5Phase 4 1No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- PRO for Fighting FT in Ovarian CancerRecruitingNCT06032975
- MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.RecruitingNCT05255471Phase 3
- Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational StudyStatus unknownNCT04091204Phase 2
- Observational Retrospective Study on Treatment and Outcomes in Patients With Low-grade Serous Ovarian CancerStatus unknownNCT02408536
- Bevacizumab Beyond Progression in Platinum Sensitive Ovarian CancerStatus unknownNCT01802749Phase 3
- Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With BevacizumabStatus unknownNCT01706120Phase 4
- Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian CancerCompletedNCT01644825Phase 2
- Pathway to Diagnosis of Ovarian CancerStatus unknownNCT01061619
- Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian CancerStatus unknownNCT00660842Phase 3
- Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free IntervalStatus unknownNCT00657878Phase 3
- MITO-6: Capecitabine in Platinum Resistant Ovarian CancerCompletedNCT00403429Phase 2
- MITO-5: Weekly Carboplatin and Paclitaxel as First Line Chemotherapy for Elderly Patients With Ovarian CancerCompletedNCT00401674Phase 2
- MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian CancerStatus unknownNCT00326456Phase 3